Xcout Intel
Cortexyme, Inc.
Cortexyme, Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutics for major degenerative disorders.
Subscribe to see Cortexyme, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Cortexyme, Inc. at a glance
Cortexyme, Inc. is a life sciences company headquartered in United States. Its most recent funding round raised $84.5M in May 2018. Xcout tracks 7 named people at Cortexyme, Inc., including Dirk Thye (Chief Executive Officer, Chief Medical Officer, and Board Member).
Cortexyme, Inc. leadership
- Dirk ThyeChief Executive Officer, Chief Medical Officer, and Board Member
- Charles RyanPresident
- Brendan HannahChief Operating Officer and Chief Business Officer
- Brigette RobertsChief Corporate Affairs Officer and Board Member
- Christopher SennerChief Financial Officer, Exelixis
- June BrayPreviously SVP, Global Regulatory Affairs and Medical Writing, Allergan
1 more named person on record for Cortexyme, Inc., with roles, board committees and tenure — see the full roster →
Cortexyme, Inc. funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $84.5M | — | |
| SEC Form D filing | $7.6M | — | |
| SEC Form D filing | $7.9M | — | |
| Series A | $15M | 1 named | |
| Seed | $1M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Cortexyme, Inc. competitors
A few of Cortexyme, Inc.'s closest competitors — see the full list of competitors and alternatives →
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations. The company, previously known as Cortexyme, Inc., officially rebranded as Quince Therapeutics, Inc. in August 2022. Established in 2012, Quince Therapeutics is headquartered in South San Francisco, California.
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Alzheon, Inc. is a clinical-stage biopharmaceutical company headquartered in Framingham, Massachusetts. Founded in 2013, the company is dedicated to developing a broad portfolio of investigational therapeutic products for neurodegenerative disorders, including Alzheimer's disease. Its research centers on advancing disease-modifying treatments for patients with cognitive decline.
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Alzinova AB is a Swedish clinical-stage biopharmaceutical company that develops disease-modifying treatments and vaccines targeting Alzheimer's disease. Utilizing its proprietary AβCC Peptide technology, the company focuses on creating therapeutics for Alzheimer's patients to address high unmet medical needs in neurodegeneration.
Spiral Therapeutics Inc. is a clinical-stage pharmaceutical company based in South San Francisco, California, focused on delivering targeted therapies for inner ear conditions.
Get Cortexyme, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Cortexyme, Inc. in Xcout Intel
- 7 named people with titles, LinkedIn and board committees
- 5 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access